返回 
加入收藏
口服二氢吡啶类钙通道阻滞剂治疗心血管疾病的快速综合评价广西专家共识
x
请在关注微信后，向客服人员索取文件
| 篇名： | 口服二氢吡啶类钙通道阻滞剂治疗心血管疾病的快速综合评价广西专家共识 |
| TITLE： | Guangxi expert consensus on rapid comprehensive evaluation of oral dihydropyridine calcium channel blockers in the treatment of cardiovascular disease |
| 摘要： | 目的 对广西地区临床常用口服二氢吡啶类钙通道阻滞剂（DHPCCBs）进行快速综合评价，为临床用药及医疗机构遴选药物提供科学依据。方法基于广西壮族自治区二级及以上级别公立医疗机构实际用药数据，以国家集采目录为基准，遴选出临床常用口服DHPCCBs。广西药学会循证药学专业委员会组织区内多家医疗机构有关专家，参考《中国医疗机构药品评价与遴选快速指南（第二版）》，结合最新的循证医学研究成果，并广泛征求临床和药学专家建议，从药学特性、有效性、安全性、经济性及其他属性5个关键维度对遴选出的口服DHPCCBs进行量化评分，最终制定《口服二氢吡啶类钙通道阻滞剂治疗心血管疾病的快速综合评价广西专家共识》。结果共遴选出30种临床常用口服DHPCCBs。其中以苯磺酸氨氯地平片（晖致）的综合评分最高（81.79分），其优势主要体现在药学特性、有效性和其他属性3个方面；综合评分排第2、3名的分别为苯磺酸氨氯地平片（重庆药友）和苯磺酸氨氯地平片（苏州东瑞），分别为81.66、81.60分。结论本共识可为广西地区口服DHPCCBs的临床合理应用以及医疗机构药品目录的遴选提供指导建议和决策支持。 |
| ABSTRACT： | OBJECTIVE To conduct a rapid and comprehensive evaluation of commonly used oral dihydropyridine calcium channel blockers （DHP CCBs） in Guangxi， and provide scientific basis for clinical medication and drug selection in medical institutions. METHODS Based on the actual drug use data of public medical institutions at the second level and above in Guangxi Zhuang Autonomous Region， and based on the national centralized collection catalog， commonly used oral DHP CCBs were selected. The Professional Committee of Evidence-based Pharmacy of the Guangxi Pharmaceutical Association organized relevant experts from multiple medical institutions in the region to conduct a quantitative scoring of the selected oral DHP CCBs from five key dimensions of pharmaceutical characteristics， effectiveness， safety， economy， and other attributes， by referring to the Quick Guideline for Drug Evaluation and Selection in Chinese Medical Institutions （the Second Edition）， combined with the latest evidence-based medical research results， and widely soliciting suggestions from clinical and pharmaceutical experts. Finally， the Guangxi Expert Consensus on Rapid Comprehensive Evaluation of Oral Dihydropyridine Calcium Channel Blockers in the Treatment of Cardiovascular Disease was formulated. RESULTS A total of 30 commonly used oral DHP CCBs were selected. Among them， Amlodipine besylate tablets （Huizhi） demonstrated superior comprehensive performance （81.79 points）， excelling particularly in pharmaceutical properties， effectiveness and other attributes. The compound scores of Amlodipine besylate tablets （Chongqing Yaoyou） and Amlodipine besylate tablets （Suzhou Dongrui） ranked second and third respectively， with scores of 81.66 and 81.60 points. CONCLUSIONS This consensus can provide guidance and decision-making support for the rational clinical application of oral DHP CCBs in Guangxi Region and the selection of drug directories in medical institutions. |
| 期刊： | 2025年第36卷第07期 |
| 作者： | 周思茹；丘岳；申伟培；黄振光；陈晓宇；张宏亮 |
| AUTHORS： | ZHOU Siru，QIU Yue，SHEN Weipei，HUANG Zhenguang，CHEN Xiaoyu，ZHANG Hongliang |
| 关键字： | 二氢吡啶类钙通道阻滞剂；心血管疾病；快速综合评价；专家共识；广西 |
| KEYWORDS： | dihydropyridine calcium channel blockers； cardiovascular disease； rapid comprehensive evaluation； expert |
| 阅读数： | 5 次 |
| 本月下载数： | 0 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
